Vertex Pharmaceuticals Incorporated to acquire Alpine Immune Sciences, Inc. for $4.9 billion in cash
Apr 10, 2024•over 1 year ago
Acquiring Company
Vertex Pharmaceuticals Incorporated
Acquired Company
Alpine Immune Sciences
BostonSeattleTherapeuticsBiotechnologyHealth CareBiotechnologyDescription
Vertex Pharmaceuticals Incorporated and Alpine Immune Sciences, Inc. have entered into a definitive agreement under which Vertex will acquire Alpine for $65 per share in cash, totaling approximately $4.9 billion. This strategic acquisition aims to leverage the scientific innovation of Alpine to create transformative medicines targeting serious diseases with high unmet need in specialty markets.
M&A Insights
Based on deal dataIntegration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed